Evidence map›Paper›PMID 35625966›Full record

ReviewCancers2022

Using GPCRs as Molecular Beacons to Target Ovarian Cancer with Nanomedicines.

Riya Khetan, Cintya Dharmayanti, Todd A Gillam, Eric Kübler, Manuela Klingler-Hoffmann, Carmela Ricciardelli, Martin K Oehler, Anton Blencowe, Sanjay Garg, Hugo Albrecht

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Cancer chemoprevention: signaling pathways and strategic approaches.Signal transduction and targeted therapy · 2025
    Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Riya KhetanClinical and Health Sciences, University of South Australia, Adelaide, SA 5001, Australia.ORCID 0000-0001-5166-8930
Cintya DharmayantiApplied Chemistry and Translational Biomaterials Group, Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, Australia.ORCID 0000-0003-3991-3416
Todd A GillamApplied Chemistry and Translational Biomaterials Group, Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, Australia.
Eric KüblerInstitute for Chemistry and Bioanalytics, School of Life Sciences, University of Applied Sciences and Arts Northwestern Switzerland FHNW, 4132 Muttenz, Switzerland.ORCID 0000-0002-5185-8934
Manuela Klingler-HoffmannClinical and Health Sciences, University of South Australia, Adelaide, SA 5001, Australia.
Carmela RicciardelliDiscipline of Obstetrics and Gynecology, School of Medicine, Robinson Research Institute, University of Adelaide, Adelaide, SA 5005, Australia.ORCID 0000-0001-7415-1854
Martin K OehlerDiscipline of Obstetrics and Gynecology, School of Medicine, Robinson Research Institute, University of Adelaide, Adelaide, SA 5005, Australia.
Anton BlencoweApplied Chemistry and Translational Biomaterials Group, Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, Australia.ORCID 0000-0002-7630-4874
Sanjay GargCentre for Pharmaceutical Innovation, Clinical and Health Sciences, University of South Australia, Adelaide, SA 5001, Australia.ORCID 0000-0001-7253-2629
Hugo AlbrechtClinical and Health Sciences, University of South Australia, Adelaide, SA 5001, Australia.ORCID 0000-0002-3951-1866
University of South Australia · AUFHNW University of Applied Sciences and Arts · CHRoyal Adelaide Hospital · AUThe University of Adelaide · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The five-year survival rate for women with ovarian cancer is very poor despite radical cytoreductive surgery and chemotherapy. Although most patients initially respond to platinum-based chemotherapy, the majority experience recurrence and ultimately develop chemoresistance, resulting in fatal outcomes. The current administration of cytotoxic compounds is hampered by dose-limiting severe adverse effects. There is an unmet clinical need for targeted drug delivery systems that transport chemotherapeutics selectively to tumor cells while minimizing off-target toxicity. G protein-coupled receptors (GPCRs) are the largest family of membrane receptors, and many are overexpressed in solid tumors, including ovarian cancer. This review summarizes the progress in engineered nanoparticle research for drug delivery for ovarian cancer and discusses the potential use of GPCRs as molecular entry points to deliver anti-cancer compounds into ovarian cancer cells. A newly emerging treatment paradigm could be the personalized design of nanomedicines on a case-by-case basis.

Indexed as

active targetingdrug deliveryGPCRG protein-coupled receptorinternalizationligandnanoparticleovarian cancerreceptor

Identifiers

PMID35625966
PMCPMC9140059
OpenAlexW4280500268

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.